Purpose: We evaluated the clinical outcomes of castration resistant prostate cancer (CRPC) patients treated with Docetaxel in Taichung Veterans General Hospital.
Materials and Methods: From Dec 2004 to Feb 2015, 208 patients with castration resistant prostate cancer were treated with Docetaxel70-75mg/m2, IV, every three to four weeks or 50mg/m2, every two weeks. The PSA response, time to progression duration, overall survival and adverse events wereanalyzed.
Results: The median age of the 208 patients was 69 years (range 44–86) and the median PSA when started Docetaxel was 47 ng/ml (range 2.24–4761). The median treatment courses of the patients were 6 (range 1–44). PSA response was found in 105patients (50.5%). Twenty-eight patients (13.5%) had the phenomenon of PSA flare up. The median progression free survival was 5 months (range 0–54) and the median overall survival was 13 months (range 0–80). The most common subjective adverse effects were neutropenia. About one-third patients (35%) had grade3–4 neutropenia
Conclusion: Good PSA response and fair survival outcome were demonstrated in CRPC patients treated with docetaxel. However, high risk of neutropenia should be kept in mind.